SAN DIEGO, April 9 /PRNewswire/ -- Aurora Discovery announced today the acceptance of an additional Discovery System platform to a major Pharma customer. This marks the eighth Discovery System installed this year. The Discovery System is Aurora Discovery's latest modular automation platform providing high-throughput performance for bio-chemical and cell-based assays. The Discovery System leverages Aurora Discovery's miniaturized science technologies, including the Flying Reagent Dispenser (FRD), topology compensating Plate Reader (tcPR), and high-density 1536-well and 3456-well microplates.
"We are delighted to provide miniaturization science solutions to our customers," said Peter Coassin, President and Chief Technology Officer at Aurora Discovery. "The Discovery System enables a single scientist to screen an assay against over 100,000 compounds in a matter of hours and using less than 30 microplates. This savings in time and consumables accelerates the drug discovery process while providing Pharma significant savings."
Aurora Discovery, Inc., located in San Diego, California, is a leading provider of products and services that are used in early stage pharmaceutical research, particularly in drug discovery and chemical genomics. Aurora Discovery also is developing platforms for genotyping and proteomic applications. Aurora Discovery products include high-density microplate formats compatible for both assay and compound storage, precision sub- microliter and sub-nanoliter non-contact dispensers, multi-wavelength fluorescence detectors, and system integrations.
For more information, visit Aurora Discovery on its website at http://www.auroradiscovery.com/.
Aurora Discovery, Inc.
CONTACT: Chris Biagioli, Senior Manager, Product Marketing of AuroraDiscovery, Inc., +1-858-334-4508, email@example.com